Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin and Bortezomib in Incurable Head and Neck Adenoid Cystic Carcinoma
NCT00581360Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Nov 2007
- Primary completion
- Jun 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in adenoid cystic carcinoma (ACC), sponsored by University of Pittsburgh. Primary endpoints: Objective Response Rate up to 5 years and Stable Disease Rate up to 5 years. Started Nov 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT00581360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00581360.